Tags

Type your tag names separated by a space and hit enter

Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection.
Nephrology (Carlton) 2007; 12(1):11-7N

Abstract

AIM

Pegylated interferon (PEG-IFN) combined with ribavirin is recommended for the treatment of chronic hepatitis C virus (HCV) infection in patients without renal failure. The optimal treatment of hepatitis C in dialysis patients remains to be established. A high incidence of adverse effects has been observed with conventional interferon and PEG-IFN alpha-2b in dialysis patients.

METHODS

We conducted a prospective study to investigate the tolerability and efficacy of PEG-IFN alpha-2a (135 microg weekly for 48 weeks) in six dialysis patients with chronic HCV infection.

RESULTS

Two patients completed 48 weeks of treatment. Treatment was stopped in three patients (beyond 24 weeks) when they developed unrelated complications, and stopped in one patient due to failure of viral clearance. None required treatment discontinuation due to adverse effects, and PEG-IFN alpha-2a was subjectively well tolerated. Marrow suppression with mild anaemia, leucopenia, or thrombocytopenia remained common. Two patients (infected with genotypes 3a and 1b, respectively) had sustained virological response.

CONCLUSIONS

Results from this pilot study showed that PEG-IFN alpha-2a appeared relatively well tolerated in dialysis patients with chronic HCV infection, and about one-third of patients could achieve sustained virological response.

Authors+Show Affiliations

Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong. dtmchan@hkucc.hku.hkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17295655

Citation

Chan, Tak Mao, et al. "Pilot Study of Pegylated Interferon-alpha 2a in Dialysis Patients With Chronic Hepatitis C Virus Infection." Nephrology (Carlton, Vic.), vol. 12, no. 1, 2007, pp. 11-7.
Chan TM, Ho SK, Tang CS, et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology (Carlton). 2007;12(1):11-7.
Chan, T. M., Ho, S. K., Tang, C. S., Tse, K. C., Lam, M. F., Lai, K. N., & Yung, S. (2007). Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology (Carlton, Vic.), 12(1), pp. 11-7.
Chan TM, et al. Pilot Study of Pegylated Interferon-alpha 2a in Dialysis Patients With Chronic Hepatitis C Virus Infection. Nephrology (Carlton). 2007;12(1):11-7. PubMed PMID: 17295655.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. AU - Chan,Tak Mao, AU - Ho,Stephen K N, AU - Tang,Colin S O, AU - Tse,Kai Chung, AU - Lam,Man Fai, AU - Lai,Kar Neng, AU - Yung,Susan, PY - 2007/2/14/pubmed PY - 2007/4/24/medline PY - 2007/2/14/entrez SP - 11 EP - 7 JF - Nephrology (Carlton, Vic.) JO - Nephrology (Carlton) VL - 12 IS - 1 N2 - AIM: Pegylated interferon (PEG-IFN) combined with ribavirin is recommended for the treatment of chronic hepatitis C virus (HCV) infection in patients without renal failure. The optimal treatment of hepatitis C in dialysis patients remains to be established. A high incidence of adverse effects has been observed with conventional interferon and PEG-IFN alpha-2b in dialysis patients. METHODS: We conducted a prospective study to investigate the tolerability and efficacy of PEG-IFN alpha-2a (135 microg weekly for 48 weeks) in six dialysis patients with chronic HCV infection. RESULTS: Two patients completed 48 weeks of treatment. Treatment was stopped in three patients (beyond 24 weeks) when they developed unrelated complications, and stopped in one patient due to failure of viral clearance. None required treatment discontinuation due to adverse effects, and PEG-IFN alpha-2a was subjectively well tolerated. Marrow suppression with mild anaemia, leucopenia, or thrombocytopenia remained common. Two patients (infected with genotypes 3a and 1b, respectively) had sustained virological response. CONCLUSIONS: Results from this pilot study showed that PEG-IFN alpha-2a appeared relatively well tolerated in dialysis patients with chronic HCV infection, and about one-third of patients could achieve sustained virological response. SN - 1320-5358 UR - https://www.unboundmedicine.com/medline/citation/17295655/Pilot_study_of_pegylated_interferon_alpha_2a_in_dialysis_patients_with_chronic_hepatitis_C_virus_infection_ L2 - https://doi.org/10.1111/j.1440-1797.2006.00662.x DB - PRIME DP - Unbound Medicine ER -